At the 2025 Shanghai Stock Exchange International Investors Conference held on November 12-13, Zhang Lianshan, Global R&D President of Jiangsu Hengrui Pharmaceuticals Co., Ltd., emphasized that for Chinese pharmaceutical companies to become truly international, they must commercialize domestically developed innovative products globally within the next 15 years. Achieving $1-2 billion in overseas revenue from innovative drugs is a critical milestone to join the top tier of global pharma players.

Zhang noted that the increasing trend of multinational corporations licensing innovative products from Chinese firms in recent years reflects the growing capabilities of the domestic pharmaceutical industry.

Disclosing data from last year, Zhang revealed that HENGRUI PHARMA’s innovative drug pipeline now ranks second globally. The company has demonstrated sustained innovation in novel molecular entities, delivering multiple high-quality products. This achievement stems from over two decades of consistent investment, transitioning from generic drug development to a globally competitive innovation strategy—marking a shift from "following" to "running alongside" industry leaders. Previously ranked 19th among global innovative pharma companies, Hengrui climbed four spots year-on-year, underscoring its accelerating innovation momentum.